ArticleAsian Pacific journal of cancer prevention : APJCP2025
Plumbagin Inhibits Cadmium-Induced Interleukin-6/STAT3 Signaling in the Triple-Negative Breast Cancer Cell Line.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Differential Effects of 17β-Estradiol, Its Metabolites, and Cadmium on Cytotoxicity and Redox-Related Pathways in Doxorubicin-Sensitive and -Resistant Breast Cancer Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Transcriptomics-based analysis of key genes and potential mechanism and therapeutic agents in cadmium-induced esophageal squamous cell carcinoma progression.Scientific reports · 2025Article
- 5'-Methylthioadenosine Metabolic Reprogramming Drives H3K79 Monomethylation-Mediated PAK2 Upregulation to Promote Cadmium-Induced Breast Cancer Progression by Impairing Autophagic Flux.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Different Derivatives of Plumbagin Analogue: Bioavailability and Their Toxicity Studies.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPlumbagin has been found to reduce proinflammatory cytokine expression in activated macrophages and carrageenan-induced paw edema. Cadmium triggers the release of interleukin-6 (IL-6), a key mediator of inflammation and carcinogenesis in many cell types. The effects of plumbagin on cadmium-induced inflammation in triple-negative breast cancer cells are unknown.
methodWe investigated the effects of plumbagin on cadmium-induced IL-6 expression and signal transducer and activator of transcription 3 (STAT3) activation in MDA-MB-231, a triple-negative breast cancer cell line, using real-time PCR, ELISA, and Western blotting.
resultNon-cytotoxic concentrations of cadmium chloride at 1 and 10 μM upregulated the IL-6 mRNA expression after 3 h of exposure and increased the IL-6 release after 24 h. Plumbagin at 4 μM or more was toxic to cells after 24 h. Plumbagin at 1 μM co-treated with cadmium reduced the expression and secretion of IL-6. At 24-h post-exposure, plumbagin decreased the levels of phosphorylated STAT3 induced by cadmium.
conclusionPlumbagin inhibits cadmium-induced IL-6/STAT3 signaling in a triple-negative breast cancer cell and further in vivo studies are required to elucidate the potential use of plumbagin on cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.